Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.

doi:10.1158/0008-5472.CAN-20-0177

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.

Cancer research - 1 Apr 2021

Zhang Ping, Kitchen-Smith Isaac, Xiong Lingyun, Stracquadanio Giovanni, Brown Katherine, Richter Philipp H, Wallace Marsha D, Bond Elisabeth, Sahgal Natasha, Moore Samantha, Nornes Svanhild, De Val Sarah, Surakhy Mirvat, Sims David, Wang Xuting, Bell Douglas A, Zeron-Medina Jorge, Jiang Yanyan, Ryan Anderson J, Selfe Joanna L, Shipley Janet, Kar Siddhartha, Pharoah Paul D, Loveday Chey, Jansen Rick, Grochola Lukasz F, Palles Claire, Protheroe Andrew, Millar Val, Ebner Daniel V, Pagadala Meghana, Blagden Sarah P, Maughan Timothy S, Domingo Enric, Tomlinson Ian, Turnbull Clare, Carter Hannah, Bond Gareth L

Abstract excerpt

Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been limited by our current lack of understanding regarding both interactions of these loci with somatic cancer driver mutations and their influence on tumorigenesis. For example, although both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Carcinogenesis

Share to Drug Resistance, Neoplasm

Share to Germ-Line Mutation

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 33558336
DOI: 10.1158/0008-5472.CAN-20-0177
PMCID: PMC10266546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.PMID 33558336Read ↗

Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug responseSemantic proximity Read ↗

Common genetic variants in the TP53 pathway and their impact on cancerSemantic proximity Read ↗

The importance of p53 pathway genetics in inherited and somatic cancer genomes.Semantic proximity Read ↗

A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection.Semantic proximity Read ↗

Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.Semantic proximity Read ↗

Single-nucleotide polymorphisms in the p53 signaling pathway.Semantic proximity Read ↗

Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.Semantic proximity Read ↗

Clinical Outcomes of TP53 Mutations in Cancers.Semantic proximity Read ↗

Genetic Modifiers of the p53 Pathway.Semantic proximity Read ↗

Cancer risks from germline p53 mutations.Semantic proximity Read ↗

TP53 mutations in human cancers: origins, consequences, and clinical use.Semantic proximity Read ↗

Emerging insights into ethnic-specific TP53 germline variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.